News Conference News ESC 2025 Starting SGLT2 Inhibitors in the Hospital for Acute HF Gains Support Todd Neale August 30, 2025
News Conference News ESC 2025 Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF Michael O'Riordan August 29, 2025
News Conference News ESC 2024 Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery Todd Neale August 30, 2024
News Conference News ESC 2023 ESC Focused Update on HF Synthesizes New Trial Data for Practical Use L.A. McKeown September 01, 2023
News ESC 2023 Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST Michael O'Riordan August 27, 2023
News Conference News ESC 2021 PRONOUNCE: No Difference in CVD Risks With Degarelix and Leuprolide for Prostate Cancer Michael O'Riordan August 30, 2021
News Conference News ESC 2020 COVID-19 Blamed for Weaker Research Published by Top-Tier Journals in 2020 Michael O'Riordan September 04, 2020
News Conference News ESC 2020 ACE Inhibitors, ARBs Pose No Risk in COVID-19: BRACE CORONA Michael O'Riordan September 01, 2020
News Conference News ESC 2020 LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease Caitlin E. Cox August 31, 2020
News Conference News ESC 2020 PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF Todd Neale August 30, 2020
News Conference News ESC 2020 EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF Michael O'Riordan August 28, 2020
News Conference News ESC 2019 PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen Todd Neale September 01, 2019
News Conference News ESC 2019 Increasing Oral Anticoagulation Use Tied to Less Ischemic Stroke in A-fib Patients in Italy Todd Neale August 31, 2019
News Conference News ESC 2013 AQUARIUS: Aliskiren Fails Primary Endpoint But Surprises with MACE Reduction Caitlin E. Cox September 04, 2013